The current study had some limitations. First, this study was cross-sectional. Further prospective studies should assess the relationship between serum adiponectin concentrations and retinal vessel parameters of DR in type 2 diabetes. Second, we could not evaluate the effects of systemic medications on the retinal vessel parameters. Experimental and clinical studies have found that peroxisome proliferator-activated receptor (PPAR)-γ agonists, the thiazolidinediones, and PPAR-α agonists augment circulating levels of adiponectin.
53–56 In addition to increasing the circulating levels of adiponectin, the PPAR-γ and PPAR-α agonists increase AdipoR2 in macrophages.
13 Thus, further studies of the effects of systemic medications, which can increase the plasma adiponectin concentrations and the expression of AdipoR, on the retinal vessel parameter are required. Third, we did not assess the exact mechanism of the effect of adiponectin on the retinal circulation. Although the concentrations of endothelin-1 (ET-1), a potent retinal vasoconstrictor,
57 were not investigated in the current study, a previous study showed an inverse correlation between ET-1 and adiponectin in pediatric subjects.
58 Further, in experimental studies, co-infusion of adiponectin inhibited the increased perfusion pressure by ET-1 in the pump-perfused rat hindlimb
59 and blockade of ET-1 receptors increased adiponectin-mediated vasodilation in isolated mesenteric arteries.
58 Overall, because these results imply that ET-1 may counteract adiponectin-regulated retinal circulation, further investigation is required of the association between ET-1 and adiponectin in the retinal circulation. Fourth, in the present study, we measured RBF in a single arteriole. Because of the large variability in the retinal angioarchitecture among subjects, a conclusion on the entire retinal circulation cannot necessarily be drawn from results obtained from a single vessel. Indeed, the retinal LDV system enables measurement of absolute blood flow in individual retinal vessels.
60 However, because long acquisition times and high patient compliance are required, for some clinical studies, it may be feasible to measure RBF in only one major retinal vessel of each patient. Recently a different technique has been developed based on optical coherence tomography that may be capable of measuring RBF with acceptable speed.
61 This new technique may be the standard method for evaluating retinal circulation.